Polymorphisms of Interlukin-1β rs16944 confer susceptibility to myelodysplastic syndromes | Aplastic Anemia & MDS International Foundation Return to top.

Polymorphisms of Interlukin-1β rs16944 confer susceptibility to myelodysplastic syndromes

Journal Title: 
Life Sci.
Primary Author: 
Yin C
Yin C, He N, Li P, Zhang C, Yu J, Hua M, Ji C, Ma D
Original Publication Date: 
Tuesday, November 15, 2016

Genetic factors have been shown to be associated with Myelodysplastic syndromes (MDS) susceptibility. In recent years, the role of inflammation in the promotion of tumor growth is supported by a broad range of experimental and clinical evidence. But the relationship between polymorphisms in NOD-like receptor protein 3 (NLRP3) inflammasome and MDS is rarely reported. Thus, we conducted a case-control study, and genotyped five single nucleotide polymorphisms (SNPs) (NLRP3, IL-1β, IL-18, CARD8, and NF-κB) in MDS patients and healthy controls. The association of different genotypes with patient characteristics was analyzed. Comparing MDS patients with controls, GG genotype of IL-1β (rs16944) was observed to be associated with a significantly increased risk of MDS 78/166 (48.8%) vs 26/96 (27.0%), OR=2.1, CI (1.0-4.4). No significant association was identified regarding the rest of investigated polymorphisms and MDS susceptibility. Complex karyotypes were more frequent in patients with GG genotype of IL-1β (rs16944). Patients with IL-1β polymorphisms (rs16944) GG and GA had lower hemoglobin than those without. Patients with IL-1β polymorphisms (rs16944) GG had higher IPSS scores than those without IL-1β polymorphisms. In conclusion, our present data shows that the IL-1β polymorphisms (rs16944) GG were frequently occurred in MDS. IL-1β (rs16944) GG genotype might serve as a novel biomarker and potential targets for MDS.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.